Expleo Solutions Limited (EXPLEOSOL.BO) Stock Competitors & Peer Comparison
See (EXPLEOSOL.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Information Technology Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EXPLEOSOL.BO | ₹792.35 | -3.09% | 12.7B | 10.48 | ₹78.32 | N/A |
| TCS.NS | ₹2,057.50 | -0.00% | 7.6T | 14.55 | ₹144.10 | +5.25% |
| TCS.BO | ₹2,058.55 | +0.05% | 7.6T | 14.54 | ₹144.12 | +5.25% |
| INFY.BO | ₹1,069.35 | +2.59% | 4.3T | 14.97 | ₹71.59 | +4.48% |
| INFY.NS | ₹1,069.30 | +2.60% | 4.3T | 14.89 | ₹71.96 | +4.48% |
| HCLTECH.BO | ₹1,145.40 | +1.00% | 3.2T | 18.18 | ₹64.29 | +5.14% |
| HCLTECH.NS | ₹1,145.60 | +1.01% | 3.2T | 18.21 | ₹64.16 | +5.14% |
| WIPRO.NS | ₹172.72 | -0.92% | 1.8T | 13.54 | ₹12.78 | +6.36% |
| WIPRO.BO | ₹172.65 | -0.95% | 1.8T | 13.24 | ₹13.07 | +6.36% |
| LTIM.NS | ₹4,535.00 | +2.08% | 1.3T | 28.28 | ₹160.34 | +2.82% |
Stock Comparison
EXPLEOSOL.BO vs TCS.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TCS.NS has a market cap of 7.6T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while TCS.NS trades at ₹2,057.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas TCS.NS's P/E ratio is 14.55. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TCS.NS's ROE of +0.46%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TCS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TCS.NS's competition here
EXPLEOSOL.BO vs TCS.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TCS.BO has a market cap of 7.6T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while TCS.BO trades at ₹2,058.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas TCS.BO's P/E ratio is 14.54. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TCS.BO's ROE of +0.46%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TCS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TCS.BO's competition here
EXPLEOSOL.BO vs INFY.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, INFY.BO has a market cap of 4.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while INFY.BO trades at ₹1,069.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas INFY.BO's P/E ratio is 14.97. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INFY.BO's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to INFY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INFY.BO's competition here
EXPLEOSOL.BO vs INFY.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, INFY.NS has a market cap of 4.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while INFY.NS trades at ₹1,069.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas INFY.NS's P/E ratio is 14.89. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INFY.NS's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to INFY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INFY.NS's competition here
EXPLEOSOL.BO vs HCLTECH.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HCLTECH.BO has a market cap of 3.2T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while HCLTECH.BO trades at ₹1,145.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas HCLTECH.BO's P/E ratio is 18.18. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HCLTECH.BO's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HCLTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HCLTECH.BO's competition here
EXPLEOSOL.BO vs HCLTECH.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HCLTECH.NS has a market cap of 3.2T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while HCLTECH.NS trades at ₹1,145.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas HCLTECH.NS's P/E ratio is 18.21. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HCLTECH.NS's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HCLTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HCLTECH.NS's competition here
EXPLEOSOL.BO vs WIPRO.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, WIPRO.NS has a market cap of 1.8T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while WIPRO.NS trades at ₹172.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas WIPRO.NS's P/E ratio is 13.54. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to WIPRO.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to WIPRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check WIPRO.NS's competition here
EXPLEOSOL.BO vs WIPRO.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, WIPRO.BO has a market cap of 1.8T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while WIPRO.BO trades at ₹172.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas WIPRO.BO's P/E ratio is 13.24. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to WIPRO.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to WIPRO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check WIPRO.BO's competition here
EXPLEOSOL.BO vs LTIM.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, LTIM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while LTIM.NS trades at ₹4,535.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas LTIM.NS's P/E ratio is 28.28. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTIM.NS's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTIM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTIM.NS's competition here
EXPLEOSOL.BO vs TECHM.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TECHM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while TECHM.NS trades at ₹1,428.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas TECHM.NS's P/E ratio is 26.64. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TECHM.NS's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TECHM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TECHM.NS's competition here
EXPLEOSOL.BO vs TECHM.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TECHM.BO has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while TECHM.BO trades at ₹1,428.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas TECHM.BO's P/E ratio is 26.70. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TECHM.BO's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TECHM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TECHM.BO's competition here
EXPLEOSOL.BO vs LTM.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, LTM.NS has a market cap of 1.1T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while LTM.NS trades at ₹3,794.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas LTM.NS's P/E ratio is 22.20. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTM.NS's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTM.NS's competition here
EXPLEOSOL.BO vs LTIM.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, LTIM.BO has a market cap of 1.1T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while LTIM.BO trades at ₹3,790.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas LTIM.BO's P/E ratio is 24.02. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTIM.BO's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTIM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTIM.BO's competition here
EXPLEOSOL.BO vs PERSISTENT.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, PERSISTENT.BO has a market cap of 763.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while PERSISTENT.BO trades at ₹4,768.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas PERSISTENT.BO's P/E ratio is 39.69. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PERSISTENT.BO's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to PERSISTENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PERSISTENT.BO's competition here
EXPLEOSOL.BO vs PERSISTENT.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, PERSISTENT.NS has a market cap of 763.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while PERSISTENT.NS trades at ₹4,769.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas PERSISTENT.NS's P/E ratio is 40.34. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PERSISTENT.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to PERSISTENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PERSISTENT.NS's competition here
EXPLEOSOL.BO vs COFORGE.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, COFORGE.NS has a market cap of 509.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while COFORGE.NS trades at ₹1,445.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas COFORGE.NS's P/E ratio is 32.93. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to COFORGE.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to COFORGE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check COFORGE.NS's competition here
EXPLEOSOL.BO vs COFORGE.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, COFORGE.BO has a market cap of 508B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while COFORGE.BO trades at ₹1,446.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas COFORGE.BO's P/E ratio is 32.85. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to COFORGE.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to COFORGE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check COFORGE.BO's competition here
EXPLEOSOL.BO vs MPHASIS.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MPHASIS.NS has a market cap of 453.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while MPHASIS.NS trades at ₹2,241.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas MPHASIS.NS's P/E ratio is 24.28. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MPHASIS.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MPHASIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MPHASIS.NS's competition here
EXPLEOSOL.BO vs MPHASIS.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MPHASIS.BO has a market cap of 452.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while MPHASIS.BO trades at ₹2,242.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas MPHASIS.BO's P/E ratio is 24.36. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MPHASIS.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MPHASIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MPHASIS.BO's competition here
EXPLEOSOL.BO vs LTTS.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, LTTS.BO has a market cap of 341.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while LTTS.BO trades at ₹3,143.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas LTTS.BO's P/E ratio is 26.21. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTTS.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTTS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTTS.BO's competition here
EXPLEOSOL.BO vs LTTS.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, LTTS.NS has a market cap of 341.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while LTTS.NS trades at ₹3,141.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas LTTS.NS's P/E ratio is 26.18. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTTS.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTTS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTTS.NS's competition here
EXPLEOSOL.BO vs HEXT.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HEXT.NS has a market cap of 329.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while HEXT.NS trades at ₹522.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas HEXT.NS's P/E ratio is 23.83. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HEXT.NS's ROE of +0.22%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HEXT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HEXT.NS's competition here
EXPLEOSOL.BO vs TATATECH.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TATATECH.BO has a market cap of 295.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while TATATECH.BO trades at ₹703.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas TATATECH.BO's P/E ratio is 55.75. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TATATECH.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TATATECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TATATECH.BO's competition here
EXPLEOSOL.BO vs TATATECH.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TATATECH.NS has a market cap of 295B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while TATATECH.NS trades at ₹703.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas TATATECH.NS's P/E ratio is 57.94. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TATATECH.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TATATECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TATATECH.NS's competition here
EXPLEOSOL.BO vs REDINGTON.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, REDINGTON.NS has a market cap of 214.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while REDINGTON.NS trades at ₹268.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas REDINGTON.NS's P/E ratio is 12.16. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to REDINGTON.NS's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to REDINGTON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check REDINGTON.NS's competition here
EXPLEOSOL.BO vs REDINGTON.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, REDINGTON.BO has a market cap of 214.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while REDINGTON.BO trades at ₹268.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas REDINGTON.BO's P/E ratio is 14.39. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to REDINGTON.BO's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to REDINGTON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check REDINGTON.BO's competition here
EXPLEOSOL.BO vs FSL.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, FSL.BO has a market cap of 168.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while FSL.BO trades at ₹237.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas FSL.BO's P/E ratio is 25.54. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to FSL.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to FSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check FSL.BO's competition here
EXPLEOSOL.BO vs FSL.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, FSL.NS has a market cap of 168.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while FSL.NS trades at ₹237.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas FSL.NS's P/E ratio is 26.24. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to FSL.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to FSL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check FSL.NS's competition here
EXPLEOSOL.BO vs KPITTECH.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, KPITTECH.NS has a market cap of 153.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while KPITTECH.NS trades at ₹554.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas KPITTECH.NS's P/E ratio is 24.03. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to KPITTECH.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to KPITTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check KPITTECH.NS's competition here
EXPLEOSOL.BO vs HEXAWARE.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HEXAWARE.NS has a market cap of 141.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while HEXAWARE.NS trades at ₹470.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas HEXAWARE.NS's P/E ratio is 22.98. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HEXAWARE.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HEXAWARE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HEXAWARE.NS's competition here
EXPLEOSOL.BO vs ECLERX.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ECLERX.NS has a market cap of 141.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ECLERX.NS trades at ₹1,477.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ECLERX.NS's P/E ratio is 19.80. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ECLERX.NS's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ECLERX.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ECLERX.NS's competition here
EXPLEOSOL.BO vs ECLERX.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ECLERX.BO has a market cap of 141.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ECLERX.BO trades at ₹1,475.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ECLERX.BO's P/E ratio is 19.82. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ECLERX.BO's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ECLERX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ECLERX.BO's competition here
EXPLEOSOL.BO vs ZENSARTECH.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ZENSARTECH.BO has a market cap of 106.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ZENSARTECH.BO trades at ₹450.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ZENSARTECH.BO's P/E ratio is 13.85. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ZENSARTECH.BO's ROE of +0.18%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ZENSARTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ZENSARTECH.BO's competition here
EXPLEOSOL.BO vs ZENSARTECH.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ZENSARTECH.NS has a market cap of 106.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ZENSARTECH.NS trades at ₹451.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ZENSARTECH.NS's P/E ratio is 14.21. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ZENSARTECH.NS's ROE of +0.18%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ZENSARTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ZENSARTECH.NS's competition here
EXPLEOSOL.BO vs BSOFT.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, BSOFT.NS has a market cap of 78.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while BSOFT.NS trades at ₹272.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas BSOFT.NS's P/E ratio is 15.22. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to BSOFT.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to BSOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BSOFT.NS's competition here
EXPLEOSOL.BO vs BSOFT.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, BSOFT.BO has a market cap of 78.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while BSOFT.BO trades at ₹272.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas BSOFT.BO's P/E ratio is 15.21. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to BSOFT.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to BSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BSOFT.BO's competition here
EXPLEOSOL.BO vs SONATSOFTW.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SONATSOFTW.NS has a market cap of 77.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while SONATSOFTW.NS trades at ₹274.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas SONATSOFTW.NS's P/E ratio is 16.80. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SONATSOFTW.NS's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to SONATSOFTW.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SONATSOFTW.NS's competition here
EXPLEOSOL.BO vs SONATSOFTW.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SONATSOFTW.BO has a market cap of 77.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while SONATSOFTW.BO trades at ₹274.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas SONATSOFTW.BO's P/E ratio is 16.35. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SONATSOFTW.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to SONATSOFTW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SONATSOFTW.BO's competition here
EXPLEOSOL.BO vs RSYSTEMINT.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, RSYSTEMINT.BO has a market cap of 63.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while RSYSTEMINT.BO trades at ₹531.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas RSYSTEMINT.BO's P/E ratio is 106.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RSYSTEMINT.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to RSYSTEMINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMINT.BO's competition here
EXPLEOSOL.BO vs HAPPSTMNDS.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HAPPSTMNDS.BO has a market cap of 52.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while HAPPSTMNDS.BO trades at ₹344.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas HAPPSTMNDS.BO's P/E ratio is 23.16. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HAPPSTMNDS.BO's ROE of +0.13%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HAPPSTMNDS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HAPPSTMNDS.BO's competition here
EXPLEOSOL.BO vs HAPPSTMNDS.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HAPPSTMNDS.NS has a market cap of 52.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while HAPPSTMNDS.NS trades at ₹344.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas HAPPSTMNDS.NS's P/E ratio is 25.42. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HAPPSTMNDS.NS's ROE of +0.13%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HAPPSTMNDS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HAPPSTMNDS.NS's competition here
EXPLEOSOL.BO vs MASTEK.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MASTEK.BO has a market cap of 51.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while MASTEK.BO trades at ₹1,605.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas MASTEK.BO's P/E ratio is 12.53. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MASTEK.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MASTEK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MASTEK.BO's competition here
EXPLEOSOL.BO vs MASTEK.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MASTEK.NS has a market cap of 50.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while MASTEK.NS trades at ₹1,606.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas MASTEK.NS's P/E ratio is 12.52. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MASTEK.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MASTEK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MASTEK.NS's competition here
EXPLEOSOL.BO vs DATAMATICS.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DATAMATICS.NS has a market cap of 50.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while DATAMATICS.NS trades at ₹848.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas DATAMATICS.NS's P/E ratio is 26.04. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DATAMATICS.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to DATAMATICS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DATAMATICS.NS's competition here
EXPLEOSOL.BO vs DATAMATICS.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DATAMATICS.BO has a market cap of 50.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while DATAMATICS.BO trades at ₹842.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas DATAMATICS.BO's P/E ratio is 26.06. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DATAMATICS.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to DATAMATICS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DATAMATICS.BO's competition here
EXPLEOSOL.BO vs ASMTEC.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ASMTEC.BO has a market cap of 47.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ASMTEC.BO trades at ₹4,081.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ASMTEC.BO's P/E ratio is 254.01. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ASMTEC.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ASMTEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ASMTEC.BO's competition here
EXPLEOSOL.BO vs CAMS.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CAMS.NS has a market cap of 38.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while CAMS.NS trades at ₹749.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas CAMS.NS's P/E ratio is 21.24. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CAMS.NS's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CAMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CAMS.NS's competition here
EXPLEOSOL.BO vs CAMS.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CAMS.BO has a market cap of 38.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while CAMS.BO trades at ₹750.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas CAMS.BO's P/E ratio is 14.08. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CAMS.BO's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CAMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CAMS.BO's competition here
EXPLEOSOL.BO vs CIGNITITEC.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CIGNITITEC.BO has a market cap of 34.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while CIGNITITEC.BO trades at ₹1,265.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas CIGNITITEC.BO's P/E ratio is 18.46. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CIGNITITEC.BO's ROE of +0.30%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CIGNITITEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CIGNITITEC.BO's competition here
EXPLEOSOL.BO vs CIGNITITEC.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CIGNITITEC.NS has a market cap of 34.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while CIGNITITEC.NS trades at ₹1,260.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas CIGNITITEC.NS's P/E ratio is 12.14. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CIGNITITEC.NS's ROE of +0.30%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CIGNITITEC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CIGNITITEC.NS's competition here
EXPLEOSOL.BO vs SASKEN.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SASKEN.BO has a market cap of 29.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while SASKEN.BO trades at ₹1,979.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas SASKEN.BO's P/E ratio is 55.45. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SASKEN.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to SASKEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SASKEN.BO's competition here
EXPLEOSOL.BO vs SASKEN.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SASKEN.NS has a market cap of 29.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while SASKEN.NS trades at ₹1,976.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas SASKEN.NS's P/E ratio is 55.31. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SASKEN.NS's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to SASKEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SASKEN.NS's competition here
EXPLEOSOL.BO vs RPSGVENT.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, RPSGVENT.NS has a market cap of 29.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while RPSGVENT.NS trades at ₹915.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas RPSGVENT.NS's P/E ratio is -74.75. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RPSGVENT.NS's ROE of -0.04%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to RPSGVENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RPSGVENT.NS's competition here
EXPLEOSOL.BO vs RPSGVENT.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, RPSGVENT.BO has a market cap of 29.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while RPSGVENT.BO trades at ₹914.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas RPSGVENT.BO's P/E ratio is -74.46. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RPSGVENT.BO's ROE of -0.04%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to RPSGVENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RPSGVENT.BO's competition here
EXPLEOSOL.BO vs RSYSTEMS.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, RSYSTEMS.NS has a market cap of 28B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while RSYSTEMS.NS trades at ₹234.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas RSYSTEMS.NS's P/E ratio is 13.59. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RSYSTEMS.NS's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RSYSTEMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMS.NS's competition here
EXPLEOSOL.BO vs RSYSTEMS.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, RSYSTEMS.BO has a market cap of 27.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while RSYSTEMS.BO trades at ₹235.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas RSYSTEMS.BO's P/E ratio is 27.99. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RSYSTEMS.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RSYSTEMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMS.BO's competition here
EXPLEOSOL.BO vs PROTEAN.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, PROTEAN.BO has a market cap of 24B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while PROTEAN.BO trades at ₹574.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas PROTEAN.BO's P/E ratio is 21.95. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PROTEAN.BO's ROE of +0.10%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to PROTEAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PROTEAN.BO's competition here
EXPLEOSOL.BO vs PROTEAN.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, PROTEAN.NS has a market cap of 24B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while PROTEAN.NS trades at ₹574.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas PROTEAN.NS's P/E ratio is 28.03. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PROTEAN.NS's ROE of +0.10%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to PROTEAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PROTEAN.NS's competition here
EXPLEOSOL.BO vs SAKSOFT.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SAKSOFT.BO has a market cap of 22.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while SAKSOFT.BO trades at ₹167.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas SAKSOFT.BO's P/E ratio is 17.16. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SAKSOFT.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SAKSOFT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SAKSOFT.BO's competition here
EXPLEOSOL.BO vs SAKSOFT.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SAKSOFT.NS has a market cap of 22.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while SAKSOFT.NS trades at ₹167.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas SAKSOFT.NS's P/E ratio is 17.33. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SAKSOFT.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SAKSOFT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SAKSOFT.NS's competition here
EXPLEOSOL.BO vs MCLOUD.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MCLOUD.NS has a market cap of 18.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while MCLOUD.NS trades at ₹29.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas MCLOUD.NS's P/E ratio is 17.43. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MCLOUD.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MCLOUD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MCLOUD.NS's competition here
EXPLEOSOL.BO vs MCLOUD.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MCLOUD.BO has a market cap of 18B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while MCLOUD.BO trades at ₹29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas MCLOUD.BO's P/E ratio is 10.39. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MCLOUD.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MCLOUD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MCLOUD.BO's competition here
EXPLEOSOL.BO vs AURUM.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, AURUM.NS has a market cap of 17B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while AURUM.NS trades at ₹217.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas AURUM.NS's P/E ratio is -68.64. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to AURUM.NS's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to AURUM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check AURUM.NS's competition here
EXPLEOSOL.BO vs AURUM.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, AURUM.BO has a market cap of 17B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while AURUM.BO trades at ₹217.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas AURUM.BO's P/E ratio is -65.59. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to AURUM.BO's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to AURUM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check AURUM.BO's competition here
EXPLEOSOL.BO vs DSSL.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DSSL.NS has a market cap of 16.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while DSSL.NS trades at ₹1,266.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas DSSL.NS's P/E ratio is 19.90. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DSSL.NS's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to DSSL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DSSL.NS's competition here
EXPLEOSOL.BO vs DSSL.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DSSL.BO has a market cap of 16.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while DSSL.BO trades at ₹1,267.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas DSSL.BO's P/E ratio is 19.90. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DSSL.BO's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to DSSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DSSL.BO's competition here
EXPLEOSOL.BO vs NINSYS.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, NINSYS.NS has a market cap of 16.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while NINSYS.NS trades at ₹901.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas NINSYS.NS's P/E ratio is 52.31. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to NINSYS.NS's ROE of +0.42%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to NINSYS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check NINSYS.NS's competition here
EXPLEOSOL.BO vs NINSYS.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, NINSYS.BO has a market cap of 16.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while NINSYS.BO trades at ₹908.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas NINSYS.BO's P/E ratio is 52.61. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to NINSYS.BO's ROE of +0.44%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to NINSYS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check NINSYS.BO's competition here
EXPLEOSOL.BO vs ACCELYA.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ACCELYA.BO has a market cap of 16.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ACCELYA.BO trades at ₹1,097.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ACCELYA.BO's P/E ratio is 16.69. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ACCELYA.BO's ROE of +0.36%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ACCELYA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ACCELYA.BO's competition here
EXPLEOSOL.BO vs ACCELYA.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ACCELYA.NS has a market cap of 16.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ACCELYA.NS trades at ₹1,095.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ACCELYA.NS's P/E ratio is 16.63. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ACCELYA.NS's ROE of +0.36%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ACCELYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ACCELYA.NS's competition here
EXPLEOSOL.BO vs MMWL.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MMWL.BO has a market cap of 15.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while MMWL.BO trades at ₹13.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas MMWL.BO's P/E ratio is 1156.52. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MMWL.BO's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MMWL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MMWL.BO's competition here
EXPLEOSOL.BO vs EXPLEOSOL.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, EXPLEOSOL.NS has a market cap of 12.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while EXPLEOSOL.NS trades at ₹789.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas EXPLEOSOL.NS's P/E ratio is 10.84. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to EXPLEOSOL.NS's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to EXPLEOSOL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check EXPLEOSOL.NS's competition here
EXPLEOSOL.BO vs ORIENTTECH.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ORIENTTECH.NS has a market cap of 11.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ORIENTTECH.NS trades at ₹247.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ORIENTTECH.NS's P/E ratio is 255.95. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ORIENTTECH.NS's ROE of +0.01%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ORIENTTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ORIENTTECH.NS's competition here
EXPLEOSOL.BO vs 3IINFOTECH.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, 3IINFOTECH.BO has a market cap of 9.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while 3IINFOTECH.BO trades at ₹54.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas 3IINFOTECH.BO's P/E ratio is 111.67. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to 3IINFOTECH.BO's ROE of +0.02%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to 3IINFOTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check 3IINFOTECH.BO's competition here
EXPLEOSOL.BO vs PVP.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, PVP.NS has a market cap of 7.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while PVP.NS trades at ₹27.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas PVP.NS's P/E ratio is -103.26. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PVP.NS's ROE of -0.03%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to PVP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PVP.NS's competition here
EXPLEOSOL.BO vs PVP.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, PVP.BO has a market cap of 7.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while PVP.BO trades at ₹27.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas PVP.BO's P/E ratio is -84.16. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PVP.BO's ROE of -0.03%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to PVP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PVP.BO's competition here
EXPLEOSOL.BO vs XCHANGING.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, XCHANGING.NS has a market cap of 7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while XCHANGING.NS trades at ₹61.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas XCHANGING.NS's P/E ratio is 11.79. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to XCHANGING.NS's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to XCHANGING.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XCHANGING.NS's competition here
EXPLEOSOL.BO vs XCHANGING.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, XCHANGING.BO has a market cap of 7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while XCHANGING.BO trades at ₹61.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas XCHANGING.BO's P/E ratio is 11.78. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to XCHANGING.BO's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to XCHANGING.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XCHANGING.BO's competition here
EXPLEOSOL.BO vs ADSL.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ADSL.BO has a market cap of 6.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ADSL.BO trades at ₹116.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ADSL.BO's P/E ratio is 18.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ADSL.BO's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ADSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ADSL.BO's competition here
EXPLEOSOL.BO vs ADSL.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ADSL.NS has a market cap of 6.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ADSL.NS trades at ₹116.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ADSL.NS's P/E ratio is 35.40. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ADSL.NS's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ADSL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ADSL.NS's competition here
EXPLEOSOL.BO vs MINDTECK.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MINDTECK.NS has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while MINDTECK.NS trades at ₹202.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas MINDTECK.NS's P/E ratio is 21.01. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MINDTECK.NS's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MINDTECK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MINDTECK.NS's competition here
EXPLEOSOL.BO vs MINDTECK.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MINDTECK.BO has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while MINDTECK.BO trades at ₹202.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas MINDTECK.BO's P/E ratio is 21.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MINDTECK.BO's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MINDTECK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MINDTECK.BO's competition here
EXPLEOSOL.BO vs VAKRANGEE.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, VAKRANGEE.NS has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while VAKRANGEE.NS trades at ₹5.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas VAKRANGEE.NS's P/E ratio is 57.37. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to VAKRANGEE.NS's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to VAKRANGEE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check VAKRANGEE.NS's competition here
EXPLEOSOL.BO vs VAKRANGEE.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, VAKRANGEE.BO has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while VAKRANGEE.BO trades at ₹5.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas VAKRANGEE.BO's P/E ratio is 57.27. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to VAKRANGEE.BO's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to VAKRANGEE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check VAKRANGEE.BO's competition here
EXPLEOSOL.BO vs ONWARDTEC.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ONWARDTEC.BO has a market cap of 6.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ONWARDTEC.BO trades at ₹278.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ONWARDTEC.BO's P/E ratio is 14.33. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ONWARDTEC.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ONWARDTEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ONWARDTEC.BO's competition here
EXPLEOSOL.BO vs ONWARDTEC.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ONWARDTEC.NS has a market cap of 6.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while ONWARDTEC.NS trades at ₹278.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas ONWARDTEC.NS's P/E ratio is 17.53. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ONWARDTEC.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ONWARDTEC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ONWARDTEC.NS's competition here
EXPLEOSOL.BO vs TERASOFT.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TERASOFT.BO has a market cap of 5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while TERASOFT.BO trades at ₹384.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas TERASOFT.BO's P/E ratio is 20.04. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TERASOFT.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TERASOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TERASOFT.BO's competition here
EXPLEOSOL.BO vs TERASOFT.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TERASOFT.NS has a market cap of 5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while TERASOFT.NS trades at ₹383.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas TERASOFT.NS's P/E ratio is 20.00. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TERASOFT.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TERASOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TERASOFT.NS's competition here
EXPLEOSOL.BO vs DIGISPICE.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DIGISPICE.NS has a market cap of 4.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while DIGISPICE.NS trades at ₹20.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas DIGISPICE.NS's P/E ratio is -13.17. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DIGISPICE.NS's ROE of +0.09%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to DIGISPICE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DIGISPICE.NS's competition here
EXPLEOSOL.BO vs DIGISPICE.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DIGISPICE.BO has a market cap of 4.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while DIGISPICE.BO trades at ₹20.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas DIGISPICE.BO's P/E ratio is 1068.06. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DIGISPICE.BO's ROE of +0.09%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to DIGISPICE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DIGISPICE.BO's competition here
EXPLEOSOL.BO vs SILVERTUC.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SILVERTUC.NS has a market cap of 4.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while SILVERTUC.NS trades at ₹187.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas SILVERTUC.NS's P/E ratio is 18.30. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SILVERTUC.NS's ROE of +0.24%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to SILVERTUC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SILVERTUC.NS's competition here
EXPLEOSOL.BO vs SILVERTUC.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SILVERTUC.BO has a market cap of 4.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while SILVERTUC.BO trades at ₹187.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas SILVERTUC.BO's P/E ratio is 18.27. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SILVERTUC.BO's ROE of +0.24%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to SILVERTUC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SILVERTUC.BO's competition here
EXPLEOSOL.BO vs CYBERTECH.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CYBERTECH.NS has a market cap of 4.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while CYBERTECH.NS trades at ₹139.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas CYBERTECH.NS's P/E ratio is 14.06. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CYBERTECH.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CYBERTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CYBERTECH.NS's competition here
EXPLEOSOL.BO vs CYBERTECH.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CYBERTECH.BO has a market cap of 4.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while CYBERTECH.BO trades at ₹140.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas CYBERTECH.BO's P/E ratio is 14.70. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CYBERTECH.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CYBERTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CYBERTECH.BO's competition here
EXPLEOSOL.BO vs INSPIRISYS.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, INSPIRISYS.NS has a market cap of 4.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while INSPIRISYS.NS trades at ₹102.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas INSPIRISYS.NS's P/E ratio is 10.17. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INSPIRISYS.NS's ROE of +0.57%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to INSPIRISYS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INSPIRISYS.NS's competition here
EXPLEOSOL.BO vs INSPIRISYS.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, INSPIRISYS.BO has a market cap of 4.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while INSPIRISYS.BO trades at ₹102.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas INSPIRISYS.BO's P/E ratio is 10.21. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INSPIRISYS.BO's ROE of +0.57%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to INSPIRISYS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INSPIRISYS.BO's competition here
EXPLEOSOL.BO vs SIGMA.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SIGMA.BO has a market cap of 3.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while SIGMA.BO trades at ₹38.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas SIGMA.BO's P/E ratio is 16.32. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SIGMA.BO's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SIGMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SIGMA.BO's competition here
EXPLEOSOL.BO vs SIGMA.NS Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SIGMA.NS has a market cap of 3.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while SIGMA.NS trades at ₹38.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas SIGMA.NS's P/E ratio is 4.47. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SIGMA.NS's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SIGMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SIGMA.NS's competition here
EXPLEOSOL.BO vs XTGLOBAL.BO Comparison July 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, XTGLOBAL.BO has a market cap of 3.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹792.35, while XTGLOBAL.BO trades at ₹29.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 10.48, whereas XTGLOBAL.BO's P/E ratio is 40.76. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to XTGLOBAL.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to XTGLOBAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XTGLOBAL.BO's competition here